UC BRAID Center for Accelerated Innovation

描述(由申请人提供)： 加州大学加速创新中心建议创建新的机制，并利用其在诊断、治疗和设备方面的不同优势，支持将前景看好的早期发明转化为患者的利益。该中心是由加州大学戴维斯分校、加州大学欧文分校、加州大学洛杉矶分校、加州大学圣地亚哥分校和加州大学旧金山分校五所医学院组成的联盟。每个校区都有一家蓬勃发展的研究企业、国家级医学院和由临床和翻译科学奖(CTSA)资助的翻译研究所。我们的五个校区加在一起，占NHLBI赠款资金的近7%。该中心利用加州传奇的生物医学和工程生态系统的活力和创造力，并整合了我们校园内许多成功的商业、工程和健康科学项目。我们的计划将与专注于医疗创新的知名生物医药公司、风险投资公司、行业组织和非营利组织合作。该中心得到了加州大学生物医学研究加速、集成和开发(UC Braid)的支持，这是加州大学五个生物医学校区的联合努力，旨在催化和加速整个UC系统的生物医学、临床和转化研究。我们将共同努力：1)通过全面的教育、培训和指导计划，吸引加州大学心脏、肺和血液疾病创新者参与创业精神。2)征集和选择符合NHLBI使命的具有高商业潜力的技术，并解决未得到满足的医疗需求或重大科学机会。3)根据行业要求孵化我们最有前途的技术，以促进将其转化为商业产品，从而改善患者护理和增强健康。4)创建高性能、可持续的基础设施，作为学术研究中心的典范。这些计划将创建一个集成的、可持续的基础设施，以加速将我们由NHLBI资助的发现转化为市场，以促进健康和改善患者护理。 (摘要结束)

DESCRIPTION (provided by applicant): The University of California Center for Accelerated Innovation proposes to create new mechanisms and to leverage its diverse strengths in diagnostics, therapeutics, and devices to support translation of promising early-stage inventions for patient benefit. The Center is a consortium of the five UC medical campuses: UC Davis, UC Irvine, UC Los Angeles, UC San Diego, and UC San Francisco. Each campus has a thriving research enterprise, nationally ranked medical school, and translational research institute funded by Clinical and Translational Science Awards (CTSA). Together, our five campuses account for nearly 7% of NHLBI's grant funding. The Center taps into the vigor and creativity of California's legendary biomedical and engineering ecosystem and integrates the many successful business, engineering and health sciences programs at our campuses. Our program will partner with well-established biomedical companies, venture capital firms, industry organizations and nonprofits focused on medical innovation. The Center is supported by UC Biomedical Research Acceleration, Integration, and Development (UC BRAID), a joint effort of the five UC biomedical campuses designed to catalyze and accelerate biomedical, clinical, and translational research across the UC system. Together we will: 1) Engage University of California heart, lung and blood disease innovators in entrepreneurism through a comprehensive education, training and mentorship program. 2) Solicit and select technologies with high commercial potential that align with NHLBI's mission and address unmet medical needs or significant scientific opportunity. 3) Incubate our most promising technologies in accordance with industry requirements to facilitate their translation to commercial products that improve patient care and enhance health. 4) Create a high-performing, sustainable infrastructure that will serve as a model to academic research centers. These programs will create an integrated, sustainable infrastructure to accelerate the translation of our NHLBI-funded discoveries to the marketplace in order to promote health and improve patient care. (End of Abstract)